Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia

Koenraad Van Doorslaer, Laura L. Reimers, Yevgeniy Y. Studentsov, Mark H. Einstein, Robert D. Burk

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Purpose: Infection with oncogenic human papillomaviruses has been linked to the development of cervical neoplasia and cancer. The exclusive expression of E7, a viral oncogene, in infected cells makes this protein an ideal target for immunotherapy. We recently reported on the results of a trial in women with cervical carcinoma-in-situ using HspE7, a protein vaccine consisting of full length HPV16 E7 linked to a heat shock protein from M. bovis. The stimulating effects of HspE7 on specific cytotoxic T lymphocytes have been demonstrated in vitro and in (pre-)clinical trials. The induction of a B-cell response by HspE7 and its association with clinical outcome is unknown, and is the purpose of this study. Experimental design: We measured the serum IgG levels against HPV16 E7 and HPV16 and -18 VLPs using a multiplexed Luminex based assay in 57 women with CIS who received the HspE7 vaccine. Results: Vaccination with HspE7 results in a modest, yet maintained increase in HPV16 E7 specific IgG levels. While not significant, increased HPV16 E7 IgG levels appear to be correlated with a positive therapeutic effect. Women who were previously treated for recurrent disease (by LEEP) had significantly higher HPV16 E7 IgG levels compared with subjects without recurrent disease (p = 0.01). In women with recurrent disease, higher IgG levels correlated with complete pathological response. Conclusions: This study suggests that IgG levels could potentially be used as a marker for response to a therapeutic vaccine. Further translational investigations of the 'priming' of local immune responses using extirpative procedures should be explored.

Original languageEnglish (US)
Pages (from-to)208-212
Number of pages5
JournalGynecologic Oncology
Issue number2
StatePublished - Feb 2010


  • Cervical carcinoma
  • HPV
  • HspE7
  • IgG
  • Therapeutic vaccine

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia'. Together they form a unique fingerprint.

Cite this